Hemostemix (CVE:HEM) Reaches New 12-Month Low at $0.04

Hemostemix Inc (CVE:HEM) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 16500 shares trading hands. The stock had previously closed at C$0.05.

The business’s 50-day moving average price is C$0.04. The firm has a market cap of $10.53 million and a price-to-earnings ratio of -1.59.

Hemostemix Company Profile (CVE:HEM)

Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.

Read More: Support Level

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.